Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up of ABT-072 Resistance in HCV Genotype 1
NCT00872196Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABT-072 in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Apr 2009; status: completed.
02
Drugs
ABT-072
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00872196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872196.